高级检索
    杨衿记, 康劲. 劳拉替尼治疗携带ALK或ROS1基因重排非小细胞肺癌患者的首项全球多中心非盲单臂临床试验[J]. 循证医学, 2018, 18(1): 43-47. DOI: 10.12019/j.issn.1671-5144.2018.01.014
    引用本文: 杨衿记, 康劲. 劳拉替尼治疗携带ALK或ROS1基因重排非小细胞肺癌患者的首项全球多中心非盲单臂临床试验[J]. 循证医学, 2018, 18(1): 43-47. DOI: 10.12019/j.issn.1671-5144.2018.01.014
    shu
    YANG Jin-ji, KANG Jin. The First International, Multicentre, Open-Label, Single-Arm Trial about Lorlatinib in Non-Small Cell Lung Cancer with ALK or ROS1 Rearrangement[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 43-47. DOI: 10.12019/j.issn.1671-5144.2018.01.014
    Citation: YANG Jin-ji, KANG Jin. The First International, Multicentre, Open-Label, Single-Arm Trial about Lorlatinib in Non-Small Cell Lung Cancer with ALK or ROS1 Rearrangement[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 43-47. DOI: 10.12019/j.issn.1671-5144.2018.01.014
    shu

    劳拉替尼治疗携带ALK或ROS1基因重排非小细胞肺癌患者的首项全球多中心非盲单臂临床试验

    The First International, Multicentre, Open-Label, Single-Arm Trial about Lorlatinib in Non-Small Cell Lung Cancer with ALK or ROS1 Rearrangement

      摘要
      • HTML全文
      • 参考文献(10)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回